Voyager Therapeutics (NASDAQ:VYGR) Downgraded to “Hold” Rating by StockNews.com

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

A number of other research analysts have also issued reports on the company. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Citigroup started coverage on shares of Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 target price for the company. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. Finally, Wedbush began coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Stock Up 0.3 %

Shares of NASDAQ VYGR traded up $0.02 on Friday, hitting $6.27. The company had a trading volume of 372,967 shares, compared to its average volume of 632,306. The firm has a market capitalization of $342.53 million, a P/E ratio of 8.83 and a beta of 0.90. Voyager Therapeutics has a 12-month low of $5.19 and a 12-month high of $11.72. The business has a 50 day moving average of $6.59 and a two-hundred day moving average of $7.17.

Voyager Therapeutics (NASDAQ:VYGR) last released its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The company had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same quarter in the previous year, the firm earned ($0.59) EPS. On average, sell-side analysts anticipate that Voyager Therapeutics will post -0.89 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the firm’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now owns 86,001 shares in the company, valued at approximately $500,525.82. This trade represents a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in Voyager Therapeutics in the 2nd quarter worth about $85,000. SummerHaven Investment Management LLC boosted its holdings in shares of Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock worth $611,000 after buying an additional 1,921 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Voyager Therapeutics by 17.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 294,420 shares of the company’s stock worth $2,329,000 after buying an additional 44,289 shares during the period. Patriot Financial Group Insurance Agency LLC acquired a new position in shares of Voyager Therapeutics during the second quarter valued at about $1,012,000. Finally, Commonwealth Equity Services LLC boosted its position in shares of Voyager Therapeutics by 36.8% during the 2nd quarter. Commonwealth Equity Services LLC now owns 77,905 shares of the company’s stock worth $616,000 after purchasing an additional 20,950 shares in the last quarter. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.